Lead Product(s) : Oxyphencyclimine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Esteve Pharmaceuticals GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
Details : Oxyphencyclimine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urinary Bladder, Neurogenic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2011
Lead Product(s) : Oxyphencyclimine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Esteve Pharmaceuticals GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
